Melanoma Research

Papers
(The median citation count of Melanoma Research is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines26
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan19
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting17
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel17
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?17
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases17
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread16
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors15
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study13
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases13
Brain metastases during follow-up of patients with resected cutaneous melanoma12
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort12
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population12
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model10
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors10
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection10
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy10
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma9
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy9
Immunotherapy-induced granulomatous reaction in patients with melanoma9
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma9
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum9
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient8
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma8
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma8
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy8
Ultraviolet A radiation exposure and melanoma: a review8
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors8
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients8
Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis8
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis8
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression8
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers8
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma8
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients7
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study7
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight7
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study7
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti7
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series7
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis7
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity7
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature6
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins6
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition6
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis6
Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors6
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update6
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis6
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases6
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression6
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies6
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment6
Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells5
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients5
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma5
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma5
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors5
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials5
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety5
Simultaneous melanomas in the setting of multiple primary melanomas5
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma4
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II4
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era4
Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson4
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy4
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site4
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma4
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report4
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma4
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans4
The immunologic balance: three cases of rituximab-associated melanoma4
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma4
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis4
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma4
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma4
Molecular profiling of primary uveal melanoma: results of a Polish cohort4
Melanoma risk during immunomodulating treatment4
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma4
Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma4
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis4
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies3
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)3
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early acce3
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis3
Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-213
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma3
Uveal melanoma metastatic at initial diagnosis: a case series3
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma3
First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma3
Melanoma and pregnant women: a systematic review and meta-analysis3
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models3
Psychosocial wellbeing in people with melanoma in-situ: a systematic review3
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition3
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis3
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas3
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature3
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors 3
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series3
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice3
Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma3
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies2
Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients2
Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis2
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic2
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results2
The effect of COVID-19 on early melanoma detection2
Expect the unexpected: a saying to bear in mind2
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome2
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors2
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients2
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells2
Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?2
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma2
Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients2
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma2
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma2
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study2
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients2
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma2
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series2
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study2
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)2
Talimogene laherparepvec monotherapy for head and neck melanoma patients2
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma2
Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?2
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study2
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases2
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure2
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 20202
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy2
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma2
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis2
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization2
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia2
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma2
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective2
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging2
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma2
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy2
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma2
Prognostic significance of tumor budding in melanoma2
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study1
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and 1
New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report1
Connective tissue panniculitis and vitiligo in a patient with stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy1
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective1
Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas1
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma1
Melanoma cell plasticity poses diagnostic challenges: a case series1
Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization1
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice1
Nivolumab-induced immune-mediated acute gastritis in a melanoma patient1
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study1
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience1
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients1
Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing1
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma1
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort1
Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study1
The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis1
Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib1
Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis1
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report1
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene1
Use of laboratory hematology data in melanoma research: comments on “A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio” Melanoma Res 1
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy1
Fertility preservation for patients with melanoma1
A survey of skin check rates in an outpatient oncology melanoma clinic1
Cardiovascular disease and malignant melanoma1
Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature1
Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma1
Management of metastatic bone disease of melanoma1
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature1
Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma1
Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea1
Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)1
Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients1
Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma1
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum1
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio1
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD11
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma1
Regorafenib in patients with pretreated advanced melanoma: a single-center case series1
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients1
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab1
Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study1
Melanoma risk prediction based on a polygenic risk score and clinical risk factors1
Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma1
Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlle1
The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease1
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma1
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma1
Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study1
Perioperative neutrophil-to-lymphocyte ratio in patients with melanoma: a pilot study assessing surgical stress after sentinel lymph node biopsy1
Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study1
Novel strategy for applying hierarchical density-based spatial clustering of applications with noise towards spectroscopic analysis and detection of melanocytic lesions1
Total body skin examination visits by dermatology providers in the 2011–2016 National Ambulatory Medical Care Survey1
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy1
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-int1
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma1
Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report1
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio1
Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green1
0.065001010894775